- Trials with a EudraCT protocol (512)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
512 result(s) found for: kidney cancer.
Displaying page 16 of 26.
EudraCT Number: 2016-001881-27 | Sponsor Protocol Number: WO39210 | Start Date*: 2017-03-01 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developi... | |||||||||||||
Medical condition: Patients at high risk of Renal Cell Carcinoma (RCC) recurrence after nephrectomy and select patients with metastatic RCC recurrence who have undergone complete metastasectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) BE (Completed) PL (Completed) ES (Completed) IE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006210-14 | Sponsor Protocol Number: 20080579 | Start Date*: 2009-04-30 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastat... | |||||||||||||
Medical condition: Metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000062-20 | Sponsor Protocol Number: 3066K1-404-WW | Start Date*: 2007-11-22 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Global Medical Affairs | ||
Full Title: A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy | ||
Medical condition: Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) HU (Completed) DE (Completed) SE (Completed) FI (Completed) NL (Completed) ES (Completed) GB (Completed) AT (Completed) DK (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002732-24 | Sponsor Protocol Number: FP2CLI001 | Start Date*: 2018-11-29 | |||||||||||
Sponsor Name:Faron Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase I/II Open–Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in ... | |||||||||||||
Medical condition: Selected solid tumours; - cutaneous melanoma - pancreatic ductal adenocarcinoma - ovarian cancer - colorectal adenocarcinoma - hepatocellular carcinoma - gallbladder cancer and cholangiocarcinoma... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001271-16 | Sponsor Protocol Number: AGO-OVAR28 | Start Date*: 2022-08-01 | |||||||||||||||||||||
Sponsor Name:AGO Research GmbH | |||||||||||||||||||||||
Full Title: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) | |||||||||||||||||||||||
Medical condition: Patients with newly diagnosed, histologically confirmed, primary advanced invasive high grade epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer, FIGO stage III/IV (except FIGO ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001096-20 | Sponsor Protocol Number: 1169/2013 | Start Date*: 2014-02-19 |
Sponsor Name:Department of Molecular and Clinical Medicine; "Sapienza" University of Rome | ||
Full Title: ASSOCIATION BETWEEN PROTON-PUMP INHIBITORS (PPI) and METRONOMIC CAPECITABINE (mCAP) AS SALVAGE TREATMENT FOR PATIENTS WITH ADVANCED GASTRO-INTESTINAL TUMOURS: A RANDOMIZED PHASE II STUDY | ||
Medical condition: Patients with gastrointestinal malignancies ineligible for conventional chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001823-15 | Sponsor Protocol Number: 20CH089 | Start Date*: 2020-04-28 | ||||||||||||||||
Sponsor Name:CHU de Saint Etienne | ||||||||||||||||||
Full Title: Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study | ||||||||||||||||||
Medical condition: covid-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002085-63 | Sponsor Protocol Number: LIDO-CLOR | Start Date*: 2008-05-13 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: TREATMENT OF CHRONIC PAIN BY NEUROMODULATION WITH LOCAL ANESTHETIC (NEURALTHERAPY) IN OPERATED AND / OR IRRADIATED PATIENTS FOR HEAD AND NECK, BREST AND, INTRATHROCIC NEOPLASM | |||||||||||||
Medical condition: CHRONIC PAIN IN OPERATED AND / OR IRRADIATED PATIENTS FOR HEAD AND NECK, BREST AND, INTRATHROCIC NEOPLASM | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017840-15 | Sponsor Protocol Number: KS-2003-06 | Start Date*: 2004-05-31 |
Sponsor Name:DSC Services, s.r.o. | ||
Full Title: Srovnání účinnosti kapecitabinu (Xeloda) s kontinuálním podáním 5-fluorouracilu v předoperační konkomitantní léčbě s radioterapií u karcinomu rekta | ||
Medical condition: Rectal cancer stage II and III | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000240-16 | Sponsor Protocol Number: 20110106 | Start Date*: 2011-06-12 | |||||||||||
Sponsor Name:Skånes Onkologiska Klinik, Skåne University Hospital, Lund | |||||||||||||
Full Title: A MULTICENTER PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF 177Lu-DOTA-TATE BASED ON KIDNEY-DOSIMETRY IN PATIENTS WITH DISSEMINATED NEUROENDOCRINE TUMORS | |||||||||||||
Medical condition: Metastatic neuroendocrine tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003016-32 | Sponsor Protocol Number: APHP180690 | Start Date*: 2020-01-24 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris | ||
Full Title: Impact of aminoglycosides-based antibiotics combination and protective isolation on outcomes in critically-ill neutropenic patients with sepsis:A randomized 2 by 2 factorial design randomized pragm... | ||
Medical condition: neutropenic patients with sepsis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005111-12 | Sponsor Protocol Number: CR13 | Start Date*: 2013-05-10 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trial programme | |||||||||||||
Medical condition: metastatic or locally advanced colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000252-18 | Sponsor Protocol Number: 35RC20_9803_RePERSO | Start Date*: 2021-04-27 | |||||||||||
Sponsor Name:Rennes University Hospital | |||||||||||||
Full Title: Evaluation of treatment PERSOnalization based on its therapeutic monitoring in patients with metastatic colorectal cancer treated with regorafenib | |||||||||||||
Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004057-71 | Sponsor Protocol Number: BC-P2-2020 | Start Date*: 2021-01-12 | |||||||||||
Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS | |||||||||||||
Full Title: miRNA100 as predictor of response to anti-endocrine treatment in luminal-HER2 negative breast cancer. a prospective validation clinical trial | |||||||||||||
Medical condition: HER2 NEGATIVE/LUMINAL BREAST CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005481-35 | Sponsor Protocol Number: 2012-005481-35 | Start Date*: 2013-09-02 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A controlled, randomized, assessor blinded, open-label study to investigate whether initiation of everolimus will reduce the incidence of developing a new Squamous Cell Carcinoma (SCC) and other ma... | |||||||||||||
Medical condition: Squamous cell carcinoma (SCC) and other malignancies in renal transplanted recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005939-78 | Sponsor Protocol Number: C-II-008 | Start Date*: 2012-06-25 | |||||||||||
Sponsor Name:CESAR Central European Society for Anticancer Drug Research-EWIV | |||||||||||||
Full Title: A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study) | |||||||||||||
Medical condition: metastatic renal cell carcinoma (mRCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004111-32 | Sponsor Protocol Number: OTRAPAC | Start Date*: 2013-03-01 | |||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||
Full Title: Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application... | |||||||||||||
Medical condition: Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000528-17 | Sponsor Protocol Number: IAEA-HypoX | Start Date*: 2012-06-05 |
Sponsor Name:Department of Experimental Clinical Oncology | ||
Full Title: A randomized multicenter study of accelerated fractionated radiotherapy with or without the hypoxic radiosensitizer nimorazole in the treatment of squamous cell carcinoma of the head and neck | ||
Medical condition: Squamous Cell Carcinoma of the Head and Neck region | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SI (Completed) EE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004034-29 | Sponsor Protocol Number: A206T-G01-001 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||
Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi... | |||||||||||||
Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004985-21 | Sponsor Protocol Number: BGB-A317-A1217-302(AdvanTIG-302) | Start Date*: 2021-09-01 | |||||||||||
Sponsor Name:BeiGene, Ltd. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD L1 Selected, a... | |||||||||||||
Medical condition: Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
